We serve Chemical Name:5-amino-2-(oxolan-2-ylmethylamino)benzoic acid CAS:896717-80-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-amino-2-(oxolan-2-ylmethylamino)benzoic acid
CAS.NO:896717-80-9
Synonyms:5-amino-2-(oxolan-2-ylmethylamino)benzoic acid
Molecular Formula:C12H16N2O3
Molecular Weight:236.26700
HS Code:2932190090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:476.7ºC at 760 mmHg
Density:1.316g/cm3
Index of Refraction:1.645
PSA:84.58000
Exact Mass:236.11600
LogP:2.21210
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-amino-2-(oxolan-2-ylmethylamino)benzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-amino-2-(oxolan-2-ylmethylamino)benzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-amino-2-(oxolan-2-ylmethylamino)benzoic acid Use and application,5-amino-2-(oxolan-2-ylmethylamino)benzoic acid technical grade,usp/ep/jp grade.
Related News: The site, near Dehradun in the Himalayan foothills, will have a capacity to produce 1 billion units annually, delivering vials filled with liquid and powder, lyophilized vials, dental cartridges and prefilled syringes. 17α-(2-cyclohexylethylcarbonyl)oxy-6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid S-fluoromethyl ester manufacturers The company’s greenfield facility in Vasanthnarsapura Karnataka Industrial Area, Tumkur district, Karnataka, is under construction and is expected to be commissioned by April, 2022, well before the PLI scheme deadline of April 1, 2023. 13,24,33,43,54,84,93,103,113,123,134,144-bis(hexaoxino)[1,6-a:6′,5′-e]hexaoxan-2-ol suppliers Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. 4′-Amino-biphenyl-2-carbaldehyde oxime vendor & factory.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. 4′-Amino-biphenyl-2-carbaldehyde oxime vendor & factory.
